June 2024. Volume 20. Number 2

The use of thiopurines in inflammatory bowel disease is associated with an increased risk of cancer

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Malham M, Jansson S, Malmborg P, Olén O, Paerregaard A, Virta LJ, et al. Risk factors of cancer in pediatric-onset inflammatory bowel disease in Denmark and Finland. J Pediatr Gastroenterol Nutr. 2023;77:55-61.

Reviewers: Ochoa Sangrador C1, Ortega Páez E2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2Pediatra. CS Góngora. Distrito Granada-Metropolitano. Granada. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 15/04/2024
Acceptance date: 26/04/2024
Publication date: 08/05/2024

Abstract

Authors´ conclusions: patients with inflammatory bowel disease are at increased risk of developing cancers associated with thiopurine treatment, such as lymphoma and melanoma, as well as non-melanoma skin cancer. On the other hand, cancers associated with the disease itself, such as colorectal cancer, small intestine cancer and cholangiocarcinoma, do not seem to be associated with greater disease activity, and there could even be an inverse association with the number of relapses.

Reviewers´ commentary: the increased risk of cancer associated with the use of thiopurines is important enough to be taken into account when choosing maintenance treatment. The lower risk of cancer associated with therapeutic escalation should be confirmed in future studies.

How to cite this article

Ochoa Sangrador C, Ortega Páez E. El uso de tiopurinas en la enfermedad inflamatoria intestinal se asocia a un mayor riesgo de cáncer. Evid Pediatr. 2024;20:20.

AVC | Critically appraised articles

Malham M, Jansson S, Malmborg P, Olén O, Paerregaard A, Virta LJ, et al. Risk factors of cancer in pediatric-onset inflammatory bowel disease in Denmark and Finland. J Pediatr Gastroenterol Nutr. 2023;77:55-61.

Reviewers: Ochoa Sangrador C1, Ortega Páez E2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2Pediatra. CS Góngora. Distrito Granada-Metropolitano. Granada. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 15/04/2024
Acceptance date: 26/04/2024
Publication date: 08/05/2024

How to cite this article

Ochoa Sangrador C, Ortega Páez E. El uso de tiopurinas en la enfermedad inflamatoria intestinal se asocia a un mayor riesgo de cáncer. Evid Pediatr. 2024;20:20.

08/05/2024

Linked Comment